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It is unclear whether the antiproliferative/proapoptotic activity of oncogenes can be pharmacologically
reactivated in cancer cells. In this issue of Cancer Cell, Liu and colleagues report that a proteasome inhibitor
reactivates an MLL-AF4 controlled antitumor program to kill leukemia cells in an oncogene dose- and cell
type-dependent manner.Oncogenes, such as constitutively acti-
vated Ras, can drive tumorigenesis;
therefore, it was initially unexpected
that oncogenes also possess contex-
tual antitumor activities like causing
apoptosis and cell senescence (Lowe
et al., 2004; Serrano et al., 1997). It was
later found that while activated onco-
genes initially trigger antitumor pro-
cesses in cells, they eventually lose their
antitumor activity and drive tumorigen-
esis in a temporal and contextual manner
(Lowe et al., 2004). However, it remains
unclear whether the often hidden anti-
tumor action of a particular oncogene
can be reactivated pharmacologically
and utilized to specifically target cancer
cells. A definitive answer to this question
would unravel the mechanisms choreo-
graphing the ‘‘Jekyll and Hyde’’ actions
of oncogenes, i.e., antitumor versus
oncogenic activity, and shed light on
how to improve cancer therapy. In this
regard, Liu et al. (2014) report in this
issue of Cancer Cell that when pro-B
mixed lineage leukemia (MLL) cells are
treated with a proteasome inhibitor, the
MLL-AF4 protein level increases and
subsequently triggers an antitumor pro-
gram in concert with the pro-B cell-specific transcription factor PAX5. This
antitumor program induces both the
antiproliferative p27kip, encoded by
CDKN1B and proapoptotic caspase-8,
and ultimately leads to specific suppres-
sion of pro-B MLL-AF4 leukemia.
MLL is classified as a group of acute
leukemias, often refractory to chemo-
therapy and with poor overall prognosis,
that expresses one of a number of
different leukemogenic fusion genes con-
sisting of the 50 part ofMLL fused to one of
many genes from other chromosomes
(Krivtsov and Armstrong, 2007). MLL
fusion proteins (MLL-FPs), in concert
with the wild-type MLL protein (Thiel
et al., 2010), drive leukemogenesis mainly
through inducing the expression of HOX
genes (Ayton and Cleary, 2003; Milne
et al., 2002). Expression of MLL-AF4
tends to cause B cell lymphoblastic leuke-
mia (Krivtsov et al., 2008).
The authors previously reported that
MLL-FPs are regulated in leukemia cells
via proteolysis by the proteasome (Liu
et al., 2007), a molecular machine special-
ized in degrading proteins. Unlike many
oncogenes that are highly expressed in
cancer cells, MLL-AF4 tends to be ex-
pressed at low levels in leukemia cells.To address this distinct feature of MLL-
AF4, Liu and colleagues investigated
whether increased levels of MLL-AF4
leads to suppression of leukemia cells.
They treated various human leukemia
cell lines with the proteasome inhibitor
bortezomib, which is approved for the
treatment of multiple myeloma, to inhibit
MLL-AF4 degradation. Many key proteins
controlling cell survival and proliferation
are regulated by proteasome-mediated
proteolysis, and their levels are often
increased by treatment with bortezomib
(Frankland-Searby and Bhaumik, 2012).
Bortezomib increased levels of wild-type
MLL as well as MLL fusion proteins in all
tested leukemia cell lines. Interestingly,
pro-B MLL leukemia cell lines were more
sensitive to bortezomib-induced G2/M
cell cycle arrest and apoptosis when
compared to non-MLL pro-B leukemia
cell lines, whereas all of the cell lines
showed similar sensitivity to other
chemotherapeutic agents. Based on
these findings, the authors suspected
that MLL-AF4 participates in bortezo-
mib-induced cytotoxicity in the pro-B
MLL leukemia cells.
To explore this possibility, they demon-
strated that selective knockdown ofl 25, April 14, 2014 ª2014 Elsevier Inc. 411
Figure 1. A Model for Proteasome Inhibitor-Induced Increase of the
MLL-AF4 Level and Induction of PAX5-Dependent Transcription of
p27 in Pro-B MLL-AF4 Leukemia Cells.
The proteins are not drawn to scale, nor is the protein complex precisely
stoichiometric as shown.
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bortezomib-induced apopto-
sis in the pro-B MLL leukemia
cells. Consistently, ectopic
expression of MLL-AF4
cDNA in non-MLL pro-B leu-
kemia cells enhanced their
sensitivity to bortezomib-
induced cytotoxicity, while
ectopic expression of N-ter-
minal MLL alone without a
fusion partner failed to
enhance the sensitivity to bor-
tezomib. Collectively, these
findings uncover a crucial
role for MLL-AF4 in mediating
bortezomib-induced cytotox-
icity in pro-B MLL leukemia
cells, but not in MLL-FP acute
myeloid leukemia (AML) cells.Liu et al. (2014) further explored how
bortezomib induces apoptosis in pro-B
MLL-AF4 leukemia cells. They found that
bortezomib induced expression of FAS,
FAS ligand, and caspase-8, all important
components of an apoptotic cascade,
but did not affect the classic targets of
MLL-FPs such as HOXA9 and MEIS1.
This suggests that the increased level of
MLL-AF4 inducedbybortezomib is impor-
tant for inducing expression of these
apoptotic genes, whereas other classic
MLL-FP targets such as HOXA9 and
MEIS1 might already be expressed at a
maximal level, thus preventing their
expression from being further augmented
byadditionalMLL-AF4.However,whether
MLL-AF4 is directly involved in upregulat-
ing transcription of these proapoptotic
genes remains unclear.
Next, the authors investigated the
mechanism of bortezomib-induced cell
cycle arrest in the pro-B MLL leukemia
cells. They demonstrated that bortezomib
treatment substantially upregulated p27
at both the mRNA and protein levels,
while levels of other cell cycle proteins
remained unchanged. Upregulation of
p27 was dependent on the MLL-AF4
level as MLL-AF4 knockdown atten-
uated bortezomib-induced p27 expres-
sion. Wild-type MLL may play a role
in the upregulation of p27, because con-
current knockdown of both MLL-AF4 and
MLL impaired the induction of p27 to a
greater degree than knocking down
MLL-AF4 alone. Using a chromatin immu-
noprecipitation (ChIP) assay, Liu et al.
(2014) found that bortezomib increased412 Cancer Cell 25, April 14, 2014 ª2014 Elsrecruitment of MLL and MLL-AF4 at the
CDKN1B promoter along with P-TEFb,
resulting in enhanced p27 expression
(Figure 1).
However, these results still beg the
question of why MLL-AF4 is only critical
for bortezomib-induced cytotoxicity in
pro-B MLL leukemia cells, but not in
MLL-FP AML cells. To address this issue,
the authors explored the possibility that
pro-B cell-specific transcription factors
PAX5 and EBF1 may crosstalk with MLL-
AF4 to enhance transcription of target
genes and found that indeed PAX5 inter-
acted with MLL-AF4. Moreover, PAX5
was essential for bortezomib-mediated in-
duction of p27 as PAX5 knockdown
blocked the increase inp27 levels. Further-
more, ChIP assay, coupled with PAX5
knockdown, showed that PAX5 is required
for recruiting MLL/MLL-AF4 to the
CDKN1B promoter. However, PAX5 over-
expression alone was not sufficient to
sensitize MLL-AF9 containing THP1 cells
(AML cells) to bortezomib, indicating addi-
tional factors may also be critical in pro-B
cells. Collectively, thesedata strongly sug-
gest that bortezomib induces expression
of p27 by PAX5-mediated recruitment of
MLL-AF4 and P-TEFb (Figure 1).
Next, the authors determined whether
bortezomib selectively suppresseshuman
pro-B MLL-AF4 leukemia in vivo. They
transplanted MLL-AF4 pro-B or non-MLL
pro-B leukemia cells into immunodeficient
NOD-scid ll2rg/mice, followed by treat-
ment with or without bortezomib. Con-
sistently, they found that bortezomib
reduced the leukemia burden in miceevier Inc.with pro-B MLL-AF4 leuke-
mia, but not those with non-
MLL pro-B leukemia. Further-
more, they also showed the
effectiveness of bortezomib
for certain pro-B MLL leuke-
mia patients in a small number
of patients. Given these re-
sults, it is also interesting to
speculate whether other FDA-
approved chromatin modi-
fying drugs, such as de-
acetylase inhibitors or DNA
methyltransferase inhibitors,
can also synergize with borte-
zomib to raise MLL-AF4
levels and increase MLL-AF4
antitumor target genes to
suppress pro-B MLL-AF4
leukemia.In summary, Liu et al. (2014) have
shown that a clinically effective protea-
some inhibitor switches on the hidden
molecular tumor-suppressing networks
mediated by the leukemogenic MLL-AF4
in an oncogene dose- and cell type-spe-
cific manner. These findings demonstrate
that the hidden antitumor function of an
oncogene can be reactivated pharmaco-
logically through the use of an FDA-
approved proteasome inhibitor. Practi-
cally, these studies highlight the intriguing
possibility that stratification of leukemias
based on both their underlying oncogenic
driver mutations, such as MLL-AF4, and
their cell type may ultimately guide the
precise choice of therapeutic agents,
which may soon include proteasome
inhibitors.ACKNOWLEDGMENTS
We thank Drs. Alan Diehl andWarren Pear for stim-
ulating discussions. This work was supported in
part by grants from the NIH (R01-DK085121), Car-
ing for Carcinoid Foundation-AACR Grant Care for
Carcinoid Foundation (11-60-33), a TRP grant from
the Leukemia and Lymphoma Society, and a pilot
grant from ITMAT of the University of Pennsylvania.REFERENCES
Ayton, P.M., and Cleary, M.L. (2003). Genes Dev.
17, 2298–2307.
Frankland-Searby, S., and Bhaumik, S.R. (2012).
Biochim. Biophys. Acta 1825, 64–76.
Krivtsov, A.V., and Armstrong, S.A. (2007). Nat.
Rev. Cancer 7, 823–833.
Krivtsov, A.V., Feng, Z., Lemieux, M.E., Faber, J.,
Vempati, S., Sinha, A.U., Xia, X., Jesneck, J.,
Cancer Cell
PreviewsBracken, A.P., Silverman, L.B., et al. (2008).
Cancer Cell 14, 355–368.
Liu, H., Cheng, E.H., and Hsieh, J.J. (2007). Genes
Dev. 21, 2385–2398.
Liu, H., Westergard, T.D., Cashen, A., Piwnica-
Worms, D.R., Kumkle, L., Vij, R., Pham, C.G., Di-Persio, J., Cheng, E.H., and Hsieh, J.J. (2014).
Cancer Cell 25, this issue, 530–542.
Lowe, S.W., Cepero, E., and Evan, G. (2004). Na-
ture 432, 307–315.
Milne, T.A., Briggs, S.D., Brock, H.W.,Martin, M.E.,
Gibbs, D., Allis, C.D., and Hess, J.L. (2002). Mol.
Cell 10, 1107–1117.Cancer CelSerrano, M., Lin, A.W., McCurrach, M.E.,
Beach, D., and Lowe, S.W. (1997). Cell 88,
593–602.
Thiel, A.T., Blessington, P., Zou, T., Feather, D.,
Wu, X., Yan, J., Zhang, H., Liu, Z., Ernst, P., Kore-
tzky, G.A., and Hua, X. (2010). Cancer Cell 17,
148–159.l 25, April 14, 2014 ª2014 Elsevier Inc. 413
